Physician profile
Danielle Hartle
NPI 1073795530
$7,977.62
in general payments reported to CMS, 2019-2025
33 companies · $1,195 in 2025
The $1,195 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,417 · 2022: $735 · 2023: $1,320 · 2024: $2,310 · 2025: $1,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,825.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,296.39 | 2021-2025 | |
| Amgen INC. | $901.98 | 2023-2025 | Enbrel, Otezla, Evenity |
| Pfizer INC. | $548.15 | 2021-2025 | |
| Lilly USA, LLC | $546.43 | 2021-2024 | Taltz, Mounjaro |
| Novartis Pharmaceuticals Corporation | $435.19 | 2021-2025 | |
| Janssen Biotech, INC. | $425.85 | 2021-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $418.41 | 2021-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $300.66 | 2021-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $267.36 | 2022-2025 | Saphnelo |
| Horizon Therapeutics Plc | $252.49 | 2021-2023 | Krystexxa |
| Genzyme Corporation | $213.47 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.39 | 2021-2024 | Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $209.01 | 2021-2025 | Orencia |
| Radius Health, INC. | $171.68 | 2024-2025 | Tymlos |
| Shockwave Medical, INC | $165.22 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $124.70 | 2021-2024 | Lupkynis |
| Fresenius Kabi USA, LLC | $81.29 | 2024-2025 | Tyenne |
| Sanofi Pasteur INC. | $56.34 | 2022-2023 | |
| Organon LLC | $52.54 | 2024-2025 | Hadlima, Renflexis |
| Sobi, INC | $36.44 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $35.85 | 2022 | |
| Alexion Pharmaceuticals, INC. | $34.39 | 2024-2025 | Strensiq |
| Pacira Therapeutics, INC. | $22.30 | 2021 | |
| Mallinckrodt Hospital Products INC. | $21.62 | 2025 | Acthar |
| Actelion Pharmaceuticals US, INC. | $19.67 | 2022 | |
| Genentech USA, INC. | $19.66 | 2021 | |
| Neurelis, INC. | $18.94 | 2022 | |
| Merck Sharp & Dohme LLC | $16.87 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.80 | 2022 | |
| Ibsa Pharma INC. | $15.66 | 2022 | |
| Scilex Pharmaceuticals INC. | $14.82 | 2024 | |
| Abbott Laboratories | $14.16 | 2025 | Octrode |
| Viiv Healthcare Company | $13.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Hartle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.